News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Jennifer Marks: Closing this chapter with Georgetown Hematology/Oncology Fellowship
Photo taken from Jennifer Marks/X
Jun 16, 2024, 14:36

Jennifer Marks: Closing this chapter with Georgetown Hematology/Oncology Fellowship

Narjust Florez shared a post by Jennifer Marks, Hematologist and Oncologist at MedStar Georgetown University Hospital, on X:

“We can’t wait for you to get here!

Dana Farber Cancer Institute is so lucky to get to recruit you.“
Quoting Jennifer Marks‘s post:
“Closing this chapter with Georgetown Hematology/Oncology Fellowship. Grateful for the journey and those who made it unforgettable. Huge thanks to my co-fellows, mentors, and sponsors for shaping me into the physician I am today. Here’s to new beginnings!“
Jennifer Marks

Source: Narjust Florez/X and Jennifer Marks/X

Narjust Florez is the Associate Director of the Cancer Care Equity Program and a thoracic medical oncologist at the Dana-Farber Brigham Cancer Center. She is the principal investigator of the Sexual Health Assessment in Women with Lung Cancer (SHAWL) Study, the largest study to date evaluating sexual dysfunction in women with lung cancer. She received the 2020 Rising Star award by the LEAD National Conference for women in hematology and oncology. In addition, Dr. Florez founded the Florez Lab in 2019. The laboratory focuses on lung cancer, social justice issues in medicine, and medical education.

cancer Dana-Farber Cancer Institute Georgetown Hematology/Oncology Fellowship Jennifer Marks Narjust Florez OncoDaily Oncology
Special Coverage
Blog
Nov 13, 2024, 10:06
A first-in-class Antibody Drug Conjugate that works by directly stimulating the immune system
Blog
Nov 13, 2024, 09:55
Moderna Incorporation announced the awardees of its 2024 Australia Fellowship Program
Blog
Nov 13, 2024, 09:39
AI tools to improve diagnosis and therapy in neuro-oncology
Insight
Nov 13, 2024, 09:27
Nikki Rossetti et al. on Early-Stage Lung Cancer in the Era of Lung Cancer Screening
Blog
Nov 13, 2024, 09:14
Yüksel Ürün: Key takeaways on high-risk and locally advanced prostate cancer from António Rui Azevedo Freitas
Blog
Nov 13, 2024, 09:11
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy
Blog
Nov 13, 2024, 09:09
Yüksel Ürün: Not all that shines is Prostate cancer – a striking reminder from Daniela Oprea-Lager
Blog
Nov 13, 2024, 09:01
Updated Results with Mitazalimab as a first-line treatment for advance pancreatic cancer
Blog
Nov 13, 2024, 08:59
Miriam Mutebi: What To Expect During A Mammogram
Insight
Nov 13, 2024, 08:56
Rachel Riechelmann: Low dose Everolimus for patients with Neuroendocrine tumors
Insight
Nov 13, 2024, 08:51
Reporting pharmacogenetic variants and cancer WGS data could guide safer prescribing
Blog
Nov 13, 2024, 08:49
Yüksel Ürün: Promising findings on SGLT2 as a biomarker for papillary RCC by Erman Akkus